Latest Insider Transactions at Akero Therapeutics, Inc. (AKRO)
This section provides a real-time view of insider transactions for Akero Therapeutics, Inc. (AKRO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Akero Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Akero Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 09
2025
|
Yuan Xu |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,398
-100.0%
|
-
|
|
Dec 09
2025
|
Tomas J. Heyman |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,398
-100.0%
|
-
|
|
Dec 09
2025
|
Seth Loring Harrison |
SELL
Sale (or disposition) back to the issuer
|
Direct |
145,699
-100.0%
|
-
|
|
Dec 09
2025
|
Seth Loring Harrison |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
148,063
-100.0%
|
-
|
|
Dec 09
2025
|
Andrew Cheng President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
436,837
-100.0%
|
-
|
|
Dec 09
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
282,149
-100.0%
|
-
|
|
Dec 09
2025
|
Chou Judy |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,398
-100.0%
|
-
|
|
Dec 09
2025
|
G. Walmsley Graham |
SELL
Sale (or disposition) back to the issuer
|
Direct |
102,398
-100.0%
|
-
|
|
Dec 09
2025
|
G. Walmsley Graham |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,200,000
-100.0%
|
-
|
|
Dec 09
2025
|
William Richard White Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
57,752
-100.0%
|
-
|
|
Dec 09
2025
|
Scott A. Gangloff Chief Technology Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
26,351
-100.0%
|
-
|
|
Dec 09
2025
|
Mark T Iwicki |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,398
-100.0%
|
-
|
|
Dec 09
2025
|
Jane Henderson |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,398
-100.0%
|
-
|
|
Dec 09
2025
|
Patrick Lamy |
SELL
Sale (or disposition) back to the issuer
|
Direct |
29,891
-100.0%
|
-
|
|
Dec 09
2025
|
Catriona Yale Chief Development Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
74,800
-100.0%
|
-
|
|
Dec 09
2025
|
Jonathan Young Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
200,189
-100.0%
|
-
|
|
Dec 09
2025
|
Jonathan Young Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
60,000
-100.0%
|
-
|
|
Nov 26
2025
|
Jonathan Young Chief Operating Officer |
SELL
Bona fide gift
|
Direct |
9,259
-4.42%
|
-
|
|
Nov 25
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
152,678
+8.85%
|
$1,984,814
$13.02 P/Share
|
|
Nov 24
2025
|
Jonathan Young Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,550
+2.0%
|
$288,650
$23.51 P/Share
|
|
Nov 20
2025
|
Andrew Cheng President and CEO |
SELL
Bona fide gift
|
Direct |
74,538
-14.58%
|
-
|
|
Nov 17
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Bona fide gift
|
Direct |
37,100
-22.27%
|
-
|
|
Nov 12
2025
|
Andrew Cheng President and CEO |
SELL
Bona fide gift
|
Direct |
14,739
-2.8%
|
-
|
|
Nov 04
2025
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,266
+5.38%
|
$198,384
$24.73 P/Share
|
|
Oct 10
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-5.39%
|
$1,590,000
$53.98 P/Share
|
|
Oct 10
2025
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+5.12%
|
$570,000
$19.87 P/Share
|
|
Oct 08
2025
|
G. Walmsley Graham |
BUY
Exercise of conversion of derivative security
|
Direct |
90,832
+25.76%
|
$1,816,640
$20.53 P/Share
|
|
Oct 08
2025
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
52,212
+9.03%
|
$0
$0.62 P/Share
|
|
Oct 07
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,500
-3.51%
|
$575,000
$46.41 P/Share
|
|
Oct 07
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+6.53%
|
$350,000
$28.35 P/Share
|
|
Oct 01
2025
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
12,500
-3.03%
|
$587,500
$47.81 P/Share
|
|
Oct 01
2025
|
Jonathan Young Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+5.63%
|
$262,500
$21.1 P/Share
|
|
Sep 11
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
1,796
-0.38%
|
$77,228
$43.02 P/Share
|
|
Sep 11
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
553
-0.33%
|
$23,779
$43.02 P/Share
|
|
Sep 11
2025
|
William Richard White Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
659
-1.13%
|
$28,337
$43.02 P/Share
|
|
Sep 11
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
659
-0.72%
|
$28,337
$43.02 P/Share
|
|
Sep 11
2025
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
586
-0.3%
|
$25,198
$43.02 P/Share
|
|
Sep 10
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-2.0%
|
$1,290,000
$43.87 P/Share
|
|
Sep 10
2025
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
14,941
+1.45%
|
$194,233
$13.12 P/Share
|
|
Sep 08
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,500
-3.48%
|
$550,000
$44.53 P/Share
|
|
Sep 08
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+2.28%
|
$225,000
$18.6 P/Share
|
|
Sep 02
2025
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
12,500
-2.01%
|
$575,000
$46.83 P/Share
|
|
Sep 02
2025
|
Jonathan Young Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+5.62%
|
$262,500
$21.1 P/Share
|
|
Aug 15
2025
|
Scott A. Gangloff Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,600
+8.98%
|
$49,400
$19.62 P/Share
|
|
Aug 12
2025
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
12,500
-2.99%
|
$600,000
$48.02 P/Share
|
|
Aug 12
2025
|
Jonathan Young Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+5.62%
|
$262,500
$21.1 P/Share
|
|
Aug 12
2025
|
Jane Henderson |
SELL
Open market or private sale
|
Direct |
3,000
-24.2%
|
$141,000
$47.46 P/Share
|
|
Aug 12
2025
|
Jane Henderson |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+19.48%
|
$21,000
$7.01 P/Share
|
|
Aug 11
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-1.95%
|
$1,440,000
$48.79 P/Share
|
|
Aug 05
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,500
-3.54%
|
$612,500
$49.28 P/Share
|